August 31, 2017
2 min read

Higher FIB-4 index in patients with HBV linked to increased HCC risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for hepatocellular carcinoma was significantly higher among those with a FIB-4 index over 1.29, according to recently published data.

“Implementation of HCC surveillance is important because it is the only way to identify HCC at an early stage, which reduces disease-related morbidity and mortality,” Tai-Chung Tseng, MD, PhD, from the National Taiwan University Hospital Jinshan Branch, and colleagues wrote. “On the basis of our data, the patients with baseline FIB-4 index [lower than] 1.29 and a favorable clinical profile did not develop HCC within 16 years of follow-up. This finding helps practicing physicians identify the patients with the lowest HCC risks, who may not have additional benefit from HCC surveillance.”

To confirm the role of FIB-4 index in association with HCC risk, the researchers enrolled 2,075 treatment-naive adults with chronic HBV without cirrhosis. Additionally, the study comprised a validation cohort of 532 patients who received long-term nucleos(t)ide analogue (NUC) treatment from 2004 to 2012.

Mean FIB-4 was 1.11 (range, 0.23-6.65). During follow-up, 137 patients developed HCC with an incidence rate of 0.41 cases per 100 person-years.

All patients with an FIB-4 index over 1.29 had an increased risk for HCC (HR = 5.56; 95% CI, 3.93-7.86) vs. those with an index below 1.29. The cut-off of an index higher than 1.29 remained significant after adjusting for age, sex, alanine aminotransferase and aspartate aminotransferase, HBeAg, genotype, HBV DNA and HBsAg levels (HR = 2.27; 95% CI, 1.26-3.8).

Patients in the validation cohort received long-term NUC treatment for a mean of 6.69 years (range, 1.28-11.88 years). Ten of these patients developed HCC with an incidence rate of 0.27 cases per 100 person-years. The researchers observed that FIB-4 index higher than 1.29 at both baseline (P = .023) and 1-year (P < .001) was significantly correlated with higher risk for HCC among patients treated with NUC treatment.

“Our treatment-naive data suggests that the risks of HBV-related HCC are extremely low if the patients do not have significant fibrosis. This hypothesis was further supported by our on-treatment data that no HCC developed in NUC-treated patients FIB-4 [below] 1.29 ... which suggest an early anti-viral therapy may minimize the HCC risk,” the researchers concluded. – by Talitha Bennett


Disclosure: Tseng reports no relevant financial disclosures. Please see the full study for the other researchers’ relevant financial disclosures